In vitro Activity of Cefiderocol and Comparators against Carbapenem-Resistant Gram-Negative Pathogens from France and Belgium

In vitro Activity of Cefiderocol and Comparators against Carbapenem-Resistant Gram-Negative Pathogens from France and Belgium

Infections with carbapenem-resistant (CR) Gram-negative (GN) pathogens have increased in many countries worldwide, leaving only few therapeutic options. Cefiderocol (CFDC) is approved in Europe for the treatment of aerobic GN infections in adults with limited treatment options. This study evaluated...

Full description

Bibliographic Details
Main Authors: Saoussen Oueslati, Pierre Bogaerts, Laurent Dortet, Sandrine Bernabeu, Hend Ben Lakhal, Christopher Longshaw, Youri Glupczynski, Thierry Naas
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Antibiotics
Subjects:
CFDC
MIC
multidrug-resistant bacteria
Online Access:https://www.mdpi.com/2079-6382/11/10/1352

Similar Items

Similar Items